



(51) International Patent Classification:

C12Q 1/68 (2006.01) *C40B 40/06* (2006.01)
C07H 21/00 (2006.01) *C40B 40/10* (2006.01)
C40B 30/04 (2006.01) *G01N 33/48* (2006.01)

(21) International Application Number:

PCT/CA2014/051000

(22) International Filing Date:

17 October 2014 (17.10.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/892,094 17 October 2013 (17.10.2013) US

(71) Applicant: **CENTRE FOR ADDICTION AND MENTAL HEALTH** [CA/CA]; 33 Russell Street, Toronto, Ontario M5S 2S1 (CA).

(72) Inventors: **ZAI, Clement C.**; 250 College Street, Room R119, Toronto, Ontario M5T 1R8 (CA). **KENNEDY, James L.**; 250 College Street, Room 129, Toronto, Ontario M5T 1R8 (CA). **MUELLER, Daniel J.**; 250 College Street, Toronto, Ontario M5T 1R8 (CA).

(74) Agents: **SCHROEDER, Hans** et al.; Gowling Lafleur Henderson LLP, 160 Elgin Street, Suite 2600, Ottawa, Ontario K1P 1C3 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: GENETIC MARKERS FOR ANTIPSYCHOTIC INDUCED WEIGHT GAIN AND METHODS FOR USE THEREOF

(57) Abstract: Provided is a method of predicting a subject's weight response to antipsychotic drug treatment by obtaining a biological sample comprising genomic DNA from the subject and determining the presence or absence of one or more polymorphisms in the *GABRA2* gene of the subject, wherein the presence of said one or more polymorphisms is predictive of the subject's weight change in response to antipsychotic drug treatment. The method also may comprise additional steps including treating the subject. Kits and components thereof are also provided.

